US2021139522A1PendingUtilityA1

Antimicrobial compounds, compositions, and uses thereof

Assignee: LAKEWOOD AMEDEX INCPriority: Mar 10, 2017Filed: Mar 12, 2018Published: May 13, 2021
Est. expiryMar 10, 2037(~10.6 yrs left)· nominal 20-yr term from priority
A61P 15/02A61P 13/10A61P 17/02A61P 31/04A61K 31/7076A61K 31/706C07H 19/20C07H 19/052C07H 19/10C07H 19/04A61P 27/16A61K 31/7068A61P 31/00A61P 13/12A61P 11/00A61K 45/06A61P 3/10A61K 31/7056C07H 19/02A61P 17/00C07H 19/23A61P 13/02C07F 9/65586A61P 31/10
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antimicrobial compounds and compositions of Formulas (I) to (III) and methods of use are disclosed. Another aspect of the present disclosure provides a pharmaceutical composition comprising a compound according to Formula (I) to (III), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Another aspect of the present disclosure provides a method of treating a bacterial infection in a patient in need thereof, the method of comprising administering an effective amount of a compound according to Formula (I) to (III), or a pharmaceutically acceptable salt thereof, to the patient.

Claims

exact text as granted — not AI-modified
1 . A compound having the formula: 
       
         
           
           
               
               
           
         
         wherein:
 A is a monocyclic, bicyclic, or tricyclic carbocyclic or heterocyclic moiety, and 
 R 1  and R 2  are each a C 1 -C 8  alkyl moiety; or 
 a pharmaceutically acceptable salt thereof. 
 
       
     
     
         2 . The compound according to  claim 1 , wherein R 1  and R 2  are both butyl. 
     
     
         3 . A compound having the formula: 
       
         
           
           
               
               
           
         
         wherein:
 Q is oxygen or sulfur; 
 W is an amino-substituted or guanidino-substituted nitrogen containing heterocyclic moiety; 
 X and Z are end blocking groups; and 
 A is H, alkyl, halogen, alkoxy, alkyl-(O-alkyl), aryl, alkenyl, alkanol or phenol. 
 
       
     
     
         4 . A compound selected from any one of Cmpds 1 to 2,520 as described in TABLE 1. 
     
     
         5 . A compound having the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         6 . A pharmaceutical composition comprising a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. 
     
     
         7 . A method of treating an infection of a diabetic foot ulcer in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         8 . A method of treating a complicated urinary tract infection in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         9 . A method of treating a lung infection arising from cystic fibrosis in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         10 . A method of treating ventilator acquired pneumonia in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         11 . A method of treating an infection in a burn wound in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         12 . A method of treating otitis externa in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         13 . A method of treating bacterial vaginosis in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         14 . A method of treating impetigo in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . A method of treating an infection in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient. 
     
     
         18 . A method of treating a bladder infection in a patient in need thereof, the method comprising administering an effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, to the patient.

Join the waitlist — get patent alerts

Track US2021139522A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.